BridgeBio Oncology Therapeutics (BBOT) Change in Accured Expenses (2024 - 2026)

BridgeBio Oncology Therapeutics has reported Change in Accured Expenses for 3 years, with the latest figure at $305000.0 in Q1 2026.

• Quarterly Change in Accured Expenses rose 115.89% year-over-year to $305000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $19.9 million (up 1213.39% YoY) and the FY2025 annual result came in at $17.7 million, up 12435.46% from the prior year.
• Change in Accured Expenses eased to $305000.0 in Q1 2026 per BBOT's latest filing, from $17.7 million in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $17.7 million in Q4 2025 and troughed at -$2.4 million in Q3 2025.
• A 3-year average of $2.0 million and a median of $55808.0 in 2024 frame the typical range for Change in Accured Expenses.
• The widest YoY moves for Change in Accured Expenses: up 7645.41% in 2025, down 23140.92% in 2025.
• Over 3 years, Change in Accured Expenses stood at -$1.9 million in 2024, then jumped by 1030.63% to $17.7 million in 2025, then sank by 98.28% to $305000.0 in 2026.
• According to Business Quant data, Change in Accured Expenses over the past three periods registered $305000.0, $17.7 million, and -$2.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.